Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV at 48 Weeks

Key Points

• The study aims to analyze the resistance profile of islatravir plus lenacapavir in people with HIV at 48 weeks.
• Participants received once-weekly oral islatravir plus lenacapavir treatment.
• Resistance analysis was conducted after 48 weeks.
• Monitoring included participants with pre-existing mutations.
• High rates of viral suppression were maintained in all participants.
• No participants developed drug resistance during the study period.